Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2024 | Evaluating the role of SBRT in metastatic castrate-resistant prostate cancer

Valerie Fonteyne • 25 Jan 2024
GU Cancers 2024
Genitourinary Cancer Prostate Cancer Abiraterone
ARTO

Valerie Fonteyne, MD, PhD, Ghent University Hospital, Ghent, Belgium, discusses the current role of stereotactic radiotherapy in certain patients with metastatic castrate-resistant prostate cancer (mCRPC). Stereotactic body radiotherapy (SBRT) has shown to be effective in producing durable complete responses, and findings from the Phase II ARTO trial (NCT03449719) have additionally demonstrated the utility of SBRT with abiraterone in patients with oligometastatic castrate-resistant prostate cancer. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Valerie Fonteyne

When is adjuvant or salvage radiotherapy beneficial in prostate cancer?
1:31
When is adjuvant or salvage radiotherapy beneficial in prostate cancer?
Valerie Fonteyne • 25 Jan 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals